Late-stage evolution for Intra-Cellular; firm raises $107M, jumps to Nasdaq
By Jennifer Boggs
Friday, January 31, 2014
With an eye toward launching a Phase III program in schizophrenia later this year, Intra-Cellular Therapies Inc. priced a $107.5 million public offering after market close Thursday, selling about 6.1 million shares priced at $17.50 apiece.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.